Serotonin-1A receptor dependent modulation of pain and reward for improving therapy of chronic pain
- PMID: 29969666
- DOI: 10.1016/j.phrs.2018.06.030
Serotonin-1A receptor dependent modulation of pain and reward for improving therapy of chronic pain
Abstract
Chronic pain conditions such as low back pain and osteoarthritis are the most prominent causes of disability worldwide. Morphine and other opioid drugs are the gold standard treatment for severe pain, including surgical pain, but the use of these drugs for chronic pain is limited largely because long term use of these drugs is associated with drug abuse and hyperalgesia which produces a negative impact on the treatment. Non-addictive treatments for chronic pain are, therefore, highly needed. Commonly used opioid drugs activate mu opioid receptors, resulting in an inhibition of tonic activity of nociceptive neurons. The rewarding effects of opioid drugs are also mediated via activation of mu opioid receptors and inhibition of GABA mediated control of the activity of dopamineregic neurons. Enhanced glutamate release and greater activity of NMDA glutamate receptors is linked to the hyperalgesic effects of opioid drugs. Evidence suggests that activation of serotonin (5-hydroxytryptamine; 5-HT)-1 A receptors modulates dopamine neurotransmission to inhibit rewarding effects of drugs of abuse. Activation of these receptors inhibits glutamate release from the sensory neurons to reduce pain transmission. To help develop strategies for improving therapeutics in chronic pain, and draw research interest in the synthesis of non-addictive opioid drugs which do not predispose to hyperalgesia, the present article concerns the potential mechanism involved in 5-HT-1 A receptor mediated inhibition of pain and reward.
Keywords: 5-HT1A receptors; 8-OH-DPAT (8-hydroxy-2-di-n-propylamino tetralin); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Addiction; Buspirone (8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione); Dopamine; Dopamine (3,4-dihydroxyphenyl ethylamine); GABA (Gamma-aminobutyric acid); Hyperalgesia; Kainate ((2S,3S,4S)-3-(carboxymethyl)-4-prop-1-en-2-ylpyrrolidine-2-c…); Morphine (4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol); NMDA (N-Methyl-D-aspartic acid); Opioid; Pain; Serotonin; Serotonin (5-hydroxytryptamine); Venlafaxine ((R/S)-1-[2-(dimethylamino)-1-(4 methoxyphenyl)ethyl] cyclohexanol hydrochloride or (±)-1-[a [a- (dimethylamino)methyl] p-methoxybenzyl] cyclohexanol hydrochloride).
Copyright © 2018 Elsevier Ltd. All rights reserved.
Similar articles
-
Extending therapeutic use of psychostimulants: focus on serotonin-1A receptor.Prog Neuropsychopharmacol Biol Psychiatry. 2013 Oct 1;46:170-80. doi: 10.1016/j.pnpbp.2013.07.015. Epub 2013 Jul 29. Prog Neuropsychopharmacol Biol Psychiatry. 2013. PMID: 23906987 Review.
-
Opioid receptors beyond pain control: The role in cancer pathology and the debated importance of their pharmacological modulation.Pharmacol Res. 2020 Sep;159:104938. doi: 10.1016/j.phrs.2020.104938. Epub 2020 Jun 3. Pharmacol Res. 2020. PMID: 32504831 Review.
-
Role of serotonin 5-HT1A and opioid receptors in the antiallodynic effect of tramadol in the chronic constriction injury model of neuropathic pain in rats.Psychopharmacology (Berl). 2007 Jul;193(1):97-105. doi: 10.1007/s00213-007-0761-8. Epub 2007 Mar 29. Psychopharmacology (Berl). 2007. PMID: 17393145
-
The counteraction of opioid-induced ventilatory depression by the serotonin 1A-agonist 8-OH-DPAT does not antagonize antinociception in rats in situ and in vivo.Anesth Analg. 2009 Apr;108(4):1169-76. doi: 10.1213/ane.0b013e318198f828. Anesth Analg. 2009. PMID: 19299781
-
5-hydroxytryptamine (5-HT)1A receptors and the tail-flick response. I. 8-hydroxy-2-(di-n-propylamino) tetralin HBr-induced spontaneous tail-flicks in the rat as an in vivo model of 5-HT1A receptor-mediated activity.J Pharmacol Exp Ther. 1991 Mar;256(3):973-82. J Pharmacol Exp Ther. 1991. PMID: 1826033
Cited by
-
The OPRM1 gene and interactions with the 5-HT1a gene regulate conditioned pain modulation in fibromyalgia patients and healthy controls.PLoS One. 2022 Nov 7;17(11):e0277427. doi: 10.1371/journal.pone.0277427. eCollection 2022. PLoS One. 2022. PMID: 36342939 Free PMC article.
-
Circulating serotonin and dopamine concentrations in osteoarthritis patients: a pilot study on the effect of pelotherapy.Int J Biometeorol. 2024 Jan;68(1):69-77. doi: 10.1007/s00484-023-02571-8. Epub 2023 Nov 14. Int J Biometeorol. 2024. PMID: 37962646 Free PMC article.
-
Targeting Serotonin1A Receptors for Treating Chronic Pain and Depression.Curr Neuropharmacol. 2019;17(12):1098-1108. doi: 10.2174/1570159X17666190811161807. Curr Neuropharmacol. 2019. PMID: 31418663 Free PMC article. Review.
-
Characterization of serotonin-5-HTR1E signaling pathways and its role in cell survival.FASEB J. 2023 May;37(5):e22925. doi: 10.1096/fj.202300128R. FASEB J. 2023. PMID: 37078547 Free PMC article.
-
Central involvement of 5-HT1A receptors in antinociception induced by photobiomodulation in animal model of neuropathic pain.Lasers Med Sci. 2022 Mar;37(2):821-829. doi: 10.1007/s10103-021-03318-w. Epub 2021 Apr 22. Lasers Med Sci. 2022. PMID: 33890191
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials